Blog

Takeda’s Alofisel becomes Europe’s first allogenic stem cell therapy – PMLiVE


PMLiVE

Takeda's Alofisel becomes Europe's first allogenic stem cell therapy
PMLiVE
Takeda has chalked up a big win this week after receiving a European licence for Alofisel (darvadstrocel), marking the first approved allogenic stem cell therapy set to hit the EU market. Alofisel – previously Cx601 – is approved to treat complex

2018-03-27 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.